Why One Number Isn’t Enough for Patients - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Why One Number Isn’t Enough for Patients

Adding a comparison number may help patients interpret risk and make better decisions.

  • By

  • Kerri Miller

  • March 5, 2026

  • 2 min

Share

Clinical Scorecard: Why One Number Isn’t Enough for Patients

At a Glance

CategoryDetail
ConditionRisk Communication in Medicine
Key MechanismsUse of comparative statistics to enhance patient understanding of risk.
Target PopulationPatients receiving risk assessments, particularly those with chronic conditions like diabetes.
Care SettingClinical consultations and patient education.

Key Highlights

  • Patients find isolated risk numbers difficult to interpret.
  • Comparative statistics significantly influence patient decision-making.
  • Risk perception changes based on context and comparison.
  • Effective communication requires presenting numbers alongside relevant comparisons.
  • Silence about alternatives can inflate perceptions of treatment effectiveness.

Guideline-Based Recommendations

Diagnosis

  • Utilize comparative risk data when discussing patient diagnoses.

Management

  • Incorporate two-number comparisons in treatment discussions.

Monitoring & Follow-up

  • Regularly assess patient understanding of risk through comparative data.

Risks

  • Avoid presenting isolated risk numbers to prevent misinterpretation.

Patient & Prescribing Data

Patients with chronic conditions, such as diabetes and cancer.

Patients are more likely to consider risk-reducing medications when their risk is presented as higher than average.

Clinical Best Practices

  • Always provide context for risk numbers.
  • Use comparisons to enhance patient understanding.
  • Educate patients on the importance of understanding relative risks.

Related Resources & Content

Original Source(s)

Why One Number Isn’t Enough for Patients

  • by Kerri Miller

  • March 5, 2026

Related Content

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Serostatus May Modify RA Activity–CV Link

Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.